Followers | 12 |
Posts | 471 |
Boards Moderated | 0 |
Alias Born | 06/20/2020 |
Saturday, November 13, 2021 3:10:37 PM
When I saw the PR I immediately put in an order to sell my remaining shares then watched the price decline without my order executing. I checked my order and saw I had entered a limit order! Frantic, I entered a market order, but that was rejected because I hadn’t cancelled the limit order. So more time was lost cancelling the limit order and re-entering a market order. At this point the price was around $0.12. I did sell 1/3 of my holdings.
That the trial failed is really no surprise. Several posters, including myself, pointed out months ago why this trial was likely to fail. The GMU data told us it would fail and that data also strongly suggests that the treatment of mild COVID will fail as well. Here’s a bit of a post of mine from June 4th:
I don’t blame Leo for this trial. Time is running out for brilacidin and the opportunity to hit a home run presented itself.
What I do blame Leo for is issuing several misleading PRs, especially this one:
Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent
If you read the PR you would never suspect that remdesivir represented 99% of the 99.85% reduction in viral load. And even if you noticed the remdesivir part in the preprint paper you still wouldn’t understand how misleading the PR was (remember, the testing by the RBL was a black box type affair).
It wasn’t until I read the “Author Contributions” in the peer-reviewed paper in viruses and saw that IPIX was involved in data curation that I realized how misleading this PR was designed to be. Why? IPIX knew that remdesivir represented 99% when the PR was written. The RBL was not “independent” testing. IPIX fingerprints are on all phases of trial design, management, and publication. This was a PR that was intentionally misleading imo.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM